27 November 2015 - The Transparency Commission will consider the reimbursement of nivolumab (Opdivo) for patients with non small cell lung cancer and blinatumomab (Blincyto) for patients with acute lymphoblastic leukaemia.

For more details, go to: http://www.has-sante.fr/portail/upload/docs/application/pdf/2015-11/ordre_du_jour_ct_02122015.pdf